Bioanalytical challenges and improved detection of circulating levels of IL-13.

Abstract

BACKGROUND:

IL-13 is a key mediator of type 2 inflammation-driven diseases. Circulating IL-13 levels are very low and challenging to detect reliably. We assessed the ability of immunoassays on the Erenna(®) and IMPACT platforms to measure serum IL-13 in asthma, idiopathic pulmonary fibrosis (IPF) and atopic dermatitis (AD) patients and in healthy controls (HC).

RESULTS:

The Erenna IL-13 assay exhibited significant specificity issues and had limited ability to detect IL-13 in serum samples. The IMPACT IL-13 assay had excellent specificity and detected IL-13 in 100% of serum samples tested from asthma, IPF and AD patients and HC. Serum IL-13 levels were significantly elevated in asthma, IPF and AD patients, relative to HC.

CONCLUSION:

The IMPACT IL-13 assay had fg/ml sensitivity and excellent specificity, enabling reliable detection of circulating levels of IL-13.

• Authors: Fang Cai, Hans Hornauer, Kun Peng, Cheryl A Schofield, Heleen Scheerens, Alyssa M Morimoto
• Journal: Bioanalysis (Bioanalysis) Vol. 8 Issue 4 Pg. 323-32 (Feb 2016) ISSN: 1757-6199 [Electronic] England
• PMID: 26847873 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Interleukin-13

Topics

• Asthma (blood)
• Blood Chemical Analysis (methods)
• Case-Control Studies
• Dermatitis, Atopic (blood)
• Humans
• Interleukin-13 (blood)
• Limit of Detection
• Pulmonary Fibrosis (blood)
• Time Factors